Louvain-La-Neuve, Belgium, 28 May 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract and received the downpayment for the delivery of a Proteus®ONE solution with the European Institute of Oncology (IEO) in Milan, Italy.
The contract includes a long-term operation and maintenance agreement. The typical end-user price for a Proteus®ONE* solution with a maintenance contract is between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.
IBA was selected as the preferred partner for this project following a comprehensive vendor selection process. The hospital expects to start treating patients in 2022.
Ad Statistics
Times Displayed: 33269
Times Visited: 893 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
With a 48% market share in compact systems, IBA is further strengthening its undisputed global leadership position.
Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted to collaborate with the European Institute of Oncology to build its proton therapy center. IEO is a leader in research and cancer care, both in Italy and Europe. The IEO Advanced Radiotherapy Center in particular is ranked amongst the top five centers in Europe for technology, equipment and number of patients treated. This new collaboration strengthens our world leading position in proton therapy and demonstrates IBA’s superior product offering in the market.”
Mr. Mauro Melis, Chief Executive Officer of IEO, commented: “We are glad to partner with IBA, one of the world’s leading proton therapy systems providers. With this new proton therapy center, we will contribute to the development of international studies on the clinical use of proton therapy, and at the same time we will expand our state-of-the-art offering of cancer therapies. With its open gantry and advanced technologies, IBA’s Proteus®ONE solution is the right choice to provide greater access to proton therapy in Italy.”
Prof. Roberto Orecchia, Scientific Director of IEO, said: “Proton therapy is a superior form of radiotherapy and nowadays represents a new and better treatment choice for many cancer forms. However, there is still a lot we have to discover about proton therapy. An important aspect of entering into a partnership with IBA is to become part of its large proton therapy user community and to participate in its research collaborations on new technologies such as motion management, Proton Arc Therapy and Proton Flash Therapy. These novel techniques have the potential to change the landscape of radiotherapy and patient cancer care.”
